baclofen - Profile

What are the generic sources for baclofen and what is the scope of freedom to operate?

Baclofen is the generic ingredient in eight branded drugs marketed by Strides Pharma Intl, Amneal, Heritage, Maia Pharms Inc, Pharmobedient, Rubicon Research, Piramal Critical, Metacel Pharms Llc, Ani Pharms, Azurity, Ucb Inc, Andas 5 Holding, Aurobindo Pharma Ltd, Hibrow Hlthcare, Impax, Ivax Sub Teva Pharms, Lannett Co Inc, Mankind Pharma, Micro Labs, Northstar Hlthcare, Oxford Pharms, Ph Health, Regcon Holdings, Rising, Somerset Theraps Llc, Sun Pharm Inds Inc, Teva, Unichem, Usl Pharma, Watson Labs, Yiling, Zydus Lifesciences, and Novartis, and is included in forty-nine NDAs. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Baclofen has fourteen patent family members in eight countries.

Summary for baclofen

International Patents:	14
US Patents:	8
Tradenames:	8
Applicants:	33
NDAs:	49
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for baclofen

Paragraph IV (Patent) Challenges for BACLOFEN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FLEQSUVY	Oral Suspension	baclofen	25 mg/5 mL	215602	1	2022-05-20
OZOBAX DS	Oral Solution	baclofen	5 mg/5 mL	208193	1	2021-07-26

US Patents and Regulatory Information for baclofen

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Strides Pharma Intl	LYVISPAH	baclofen	GRANULES;ORAL	215422-001	Nov 22, 2021		DISCN	Yes	No	11,850,225		Y
Strides Pharma Intl	LYVISPAH	baclofen	GRANULES;ORAL	215422-001	Nov 22, 2021		DISCN	Yes	No	10,792,262		Y
Strides Pharma Intl	LYVISPAH	baclofen	GRANULES;ORAL	215422-001	Nov 22, 2021		DISCN	Yes	No	11,491,125		Y

Expired US Patents for baclofen

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	LIORESAL	baclofen	TABLET;ORAL	017851-001	Approved Prior to Jan 1, 1982	3,471,548
Ucb Inc	KEMSTRO	baclofen	TABLET, ORALLY DISINTEGRATING;ORAL	021589-002	Oct 30, 2003	6,024,981
Ucb Inc	KEMSTRO	baclofen	TABLET, ORALLY DISINTEGRATING;ORAL	021589-001	Oct 30, 2003	6,024,981

International Patents for baclofen

Country	Patent Number	Title	Estimated Expiration
Brazil	112022001591
Japan	7444967
European Patent Office	4003323

Investment Scenario and Fundamentals Analysis for Baclofen

Last updated: February 19, 2026

What is Baclofen, and what is its market status?

Baclofen is a muscle relaxant primarily used to treat spasticity in conditions such as multiple sclerosis (MS), spinal cord injuries, and cerebral palsy. It acts as a GABA-B receptor agonist, reducing nerve signaling that causes muscle spasms.

The global market for baclofen is valued at approximately USD 880 million in 2022, with a compound annual growth rate (CAGR) of around 4.2% forecasted through 2030 [1].

Major manufacturers include Novartis, Teva Pharmaceutical Industries, and Sandoz. Several patent expirations have occurred or are approaching, leading to increased generic competition.

What are the key drivers influencing the investment outlook?

• Patent expirations: Brand-name drugs are losing exclusivity, favoring generics. Novartis’s Baclofen patent expired in 2014, and Sandoz’s version faces patent cliffs in 2025.
• Generic penetration: Growing availability of lower-cost generic versions constrains pricing, impacting margins for branded producers.
• Pipeline developments: No significant novel formulations or delivery methods are currently under advanced clinical development, limiting innovation-driven growth.
• Pipeline competition: Alternatives such as tizanidine, gabapentin, and newer agents for spasticity are gaining market share.
• Regulatory environment: Regulatory agencies permit generic drug substitution, accelerating price erosion.
• Patient demographics: Increasing prevalence of MS and spinal cord injuries supports consistent demand.

What are the fundamental financial factors?

Factor	Details
Market size (2022)	USD 880 million
Expected CAGR (2023–2030)	4.2%
Patent expiry dates	Novartis: 2014; Sandoz: 2025
Gross margins (branded)	Approx. 65%; lower for generics due to competitive pricing
R&D expenditure	Limited; no major new formulations in pipeline
Pricing trends	Decline driven by generic competition

How does the competitive landscape impact investment?

The transition from brand to generics will continue to exert downward pressure on prices and profit margins. Companies heavily reliant on patent-protected formulations face revenue erosion unless they diversify into new indications, delivery methods, or formulations.

Cipla, Mylan, and Teva have expanded their generic portfolios, commanding a significant share in the low-cost segment. Novartis, with no new patent protections, derives limited growth from the existing formulations.

Investment considerations: Risks and opportunities

Risks:

• Price erosion from generics and biosimilars.
• Regulatory shifts favoring biosimilars, affecting revenue.
• Limited pipeline innovation reduces growth potential.
• Market saturation in developed nations as penetration approaches maximum levels.

Opportunities:

• Growth in emerging markets with increasing healthcare access.
• Opportunities in combination therapies or novel delivery (e.g., intrathecal devices).
• Potential acquisition targets with established formulations and generic manufacturing capabilities.

What are the key valuation benchmarks and metrics?

• Price-to-Earnings (P/E) ratio: Companies with significant generic exposure have P/Es typically below 15, reflecting earnings compression.
• Market share dominance: Market leaders hold approximately 50–60% of the global baclofen market.
• Revenue contribution: For generic manufacturers, baclofen can constitute 5–15% of their neuro-musculoskeletal portfolio.

Conclusion

Investing in baclofen-producing entities entails high exposure to pricing pressures due to patent expiration-driven generic entry. Companies heavily reliant on established formulations face flat or declining revenues without pipeline innovation. Opportunities exist for firms with diversified portfolios, R&D for new delivery systems, or strong presence in emerging markets.

Key Takeaways

• The global baclofen market is approaching a mature phase, with patent expirations and increased generic competition constraining growth.
• Limited pipeline activity diminishes growth prospects for traditional formulations.
• Investment risk is elevated by pricing pressures but mitigated through market expansion in emerging regions.
• Companies with diversified portfolios and innovation in delivery systems are better positioned.
• Vigilance is required regarding regulatory developments and competitive responses.

FAQs

1. Which companies dominate the baclofen market?
Novartis, Teva, and Sandoz lead, with generics supplied by multiple manufacturers globally.

2. What are the primary risks for investors?
Intensified generic competition and patent cliffs reduce profitability, along with limited pipeline innovation.

3. Are there any pipeline developments for baclofen?
No significant late-stage developments; focus remains on biosimilars and delivery system improvements, not new formulations.

4. How does patent expiration affect market dynamics?
Patent expiry allows generic entrants, substantially lowering prices and margins for branded formulations.

5. What emerging market opportunities exist?
Countries with rising healthcare infrastructure and increased MS or spinal injury prevalence provide expansion potential.

---

References

[1] Market Research Future. (2023). Baclofen Market Report.
[2] IBISWorld. (2023). Neuro-Musculoskeletal Pharmaceutical Industry Overview.